Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis
Open Access
- 1 January 2014
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (2), 569-77
- https://doi.org/10.3748/wjg.v20.i2.569
Abstract
To evaluate the effects of pentoxifylline therapy in patients with nonalcoholic fatty liver disease (NAFLD). We searched PubMed, Medline, Google Scholar, Embase, Web of Science, the Cochrane Library and the Chinese Biomedicine Database for all relevant controlled trials of pentoxifylline in patients with NAFLD from 1997 to July 2013. Five studies (3 randomized, double-blind, placebo-controlled trials and 2 prospective cohort studies with concurrent controls) were included in this meta-analysis. Statistical analysis was performed using RevMan 5.0 software. Five randomized trials of 147 patients with NAFLD/nonalcoholic steatohepatitis (NASH) were included. The results showed that compared to placebo, pentoxifylline therapy resulted in a significant decrease in body weight (P = 0.04), alanine aminotransferase (P < 0.00001), aspartate transaminase (P = 0.0006), glucose (P = 0.0008) and tumor necrosis factor-α (P = 0.007), but did not significantly affect body mass index (P = 0.28), total cholesterol (P = 0.80), triglyceride (P = 0.98), alkaline phosphatase (P = 0.29), γ-glutamyl transferase (P = 0.39) and interleukin-6 (P = 0.38). With regard to histological changes, pentoxifylline only reduced the NAFLD activity score (P < 0.00001) and improved lobular inflammation (P < 0.0001). Improvements in steatosis grade (P = 0.11), ballooning (P = 0.10) and fibrosis (P = 0.50) were not obvious. Pentoxifylline therapy results in weight loss, improved liver function and histological changes in patients with NAFLD/NASH. Therefore, pentoxifylline may be a new treatment option for NAFLD.Keywords
This publication has 40 references indexed in Scilit:
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trialJournal of Hepatology, 2011
- Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver diseaseLipids in Health and Disease, 2011
- Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meaningsJournal of Hepatology, 2010
- Preventive Effect of Pentoxifylline on Acute Radiation Damage via Antioxidant and Anti-inflammatory PathwaysDigestive Diseases and Sciences, 2009
- A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)Hepatology International, 2008
- Effects of Pentoxifylline on TNF-α Production by Peripheral Blood Mononuclear Cells in Patients with Nonalcoholic SteatohepatitisDigestive Diseases and Sciences, 2007
- Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patientsClinical Science, 2004
- PentoxifyllineJournal of the American Academy of Dermatology, 1994
- Pharmacological Approaches to the Treatment of Intermittent Claudication???Drugs & Aging, 1992
- The effects of pentoxifylline on lipopolysaccharide (LPS) fever, plasma interleukin 6 (IL 6), and tumor necrosis factor (TNF) in the ratCytokine, 1990